Literature DB >> 12384351

Antimicrobial therapy for bacillus anthracis-induced polymicrobial infection in (60)Co gamma-irradiated mice.

Thomas B Elliott1, Itzhak Brook, Rita A Harding, S Samy Bouhaouala, Michael O Shoemaker, Gregory B Knudson.   

Abstract

Challenge with both nonlethal ionizing radiation and toxigenic Bacillus anthracis spores increases the rate of mortality from a mixed bacterial infection. If biological weapons, such as B. anthracis spores, and nuclear weapons were used together, casualties could be more severe than they would be from the use of either weapon alone. We previously discovered that a polymicrobial infection developed in B6D2F(1)/J mice after nonlethal (7-Gy) (60)Co gamma irradiation and intratracheal challenge with B. anthracis Sterne spores 4 days after irradiation. In this present study, we investigated the survival of mice and the response of the polymicrobial infection during the course of antimicrobial therapy with penicillin G procaine, ofloxacin, trovafloxacin, or gatifloxacin. Survival was prolonged, but not ensured, when the mice were treated with either broad-spectrum ofloxacin or narrow-spectrum penicillin G for 7 days beginning 6 or 24 h after challenge. Survival was not prolonged when therapy was delayed more than 24 h after challenge. When these two antimicrobial agents were given for 21 days, the survival rate was increased from 0% for the controls to 38 to 63% after therapy. Therapy with trovafloxacin or gatifloxacin reduced the incidence of mixed infection and improved the rate of survival to 95% (trovafloxacin) or 79% (gatifloxacin), whereas the rate of survival for the controls was 5%. We conclude that the mixed infection induced by B. anthracis in irradiated mice complicates effective therapy with a single antimicrobial agent. To limit mortality following nonlethal irradiation and challenge with B. anthracis spores, antimicrobial therapy needs to be initiated within a few hours after challenge and continued for up to 21 days.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384351      PMCID: PMC128744          DOI: 10.1128/AAC.46.11.3463-3471.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Does the dose matter?

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

2.  Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice.

Authors:  M H Whitnall; T B Elliott; R A Harding; C E Inal; M R Landauer; C L Wilhelmsen; L McKinney; V L Miner; R M Loria; G D Ledney; T M Seed
Journal:  Int J Immunopharmacol       Date:  2000-01

3.  Susceptibility of irradiated mice to Bacillus anthracis sterne by the intratracheal route of infection.

Authors:  Itzhak Brook; Thomas B Elliott; Rita A Harding; S Samy Bouhaouala; Susan J Peacock; G David Ledney; Gregory B Knudson
Journal:  J Med Microbiol       Date:  2001-08       Impact factor: 2.472

4.  Catabolic repression of bacterial sporulation.

Authors:  P Schaeffer; J Millet; J P Aubert
Journal:  Proc Natl Acad Sci U S A       Date:  1965-09       Impact factor: 11.205

5.  Pathophysiology of anthrax.

Authors:  F Klein; J S Walker; D F Fitzpatrick; R E Lincoln; B G Mahlandt; W I Jones; J P Dobbs; K J Hendrix
Journal:  J Infect Dis       Date:  1966-04       Impact factor: 5.226

6.  In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.

Authors:  I Brook; T B Elliott; H I Pryor; T E Sautter; B T Gnade; J H Thakar; G B Knudson
Journal:  Int J Antimicrob Agents       Date:  2001-12       Impact factor: 5.283

7.  Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia.

Authors:  Pamela R Tessier; Myo-Kyoung Kim; Wen Zhou; Dawei Xuan; Chonghua Li; Min Ye; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.

Authors:  S Miyazaki; T Fujikawa; T Matsumoto; K Tateda; K Yamaguchi
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

Review 10.  Anthrax as a potential biological warfare agent.

Authors:  J C Pile; J D Malone; E M Eitzen; A M Friedlander
Journal:  Arch Intern Med       Date:  1998-03-09
View more
  3 in total

1.  Histopathology in a murine model of anthrax.

Authors:  Scott Duong; Lucius Chiaraviglio; James E Kirby
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

2.  Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Justin M Hartings; Bruce E Ivins; M Louise Pitt; David Fritz; Sarah L Norris; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

3.  Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates.

Authors:  Benny J Chen; Divino Deoliveira; Ivan Spasojevic; Gregory D Sempowski; Chen Jiang; Kouros Owzar; Xiaojuan Wang; Diane Gesty-Palmer; J Mark Cline; J Daniel Bourland; Greg Dugan; Sarah K Meadows; Pamela Daher; Garrett Muramoto; John P Chute; Nelson J Chao
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.